e4Risk®

Literature

      1. Jack, C. R., Jr. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 14, 535-562, doi:10.1016/j.jalz.2018.02.018 (2018).
      2. Crean, S. et al. Apolipoprotein E epsilon4 prevalence in Alzheimer’s disease patients varies across global populations: a systematic literature review and meta-analysis. Dementia and geriatric cognitive disorders 31, 20-30, doi:10.1159/000321984 (2011).
      3. van Duijn, C. M. et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nature genetics 7, 74-78, doi:10.1038/ng0594-74 (1994).
      4. Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 278, 1349-1356 (1997).
      5 Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921-923 (1993).
      6. Craft, S. et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease. Neurology 51, 149-153 (1998).
      7. Rabinovici, G. D. et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. Jama 321, 1286-1294, doi:10.1001/jama.2019.2000 (2019).
      8. Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama 313, 1924-1938, doi:10.1001/jama.2015.4668 (2015).
      9. Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. Jama 313, 1939-1949, doi:10.1001/jama.2015.4669 (2015).
      10. Sperling, R. in 14th Annual Mild Cognitive Impairment Symposium (Miami Beach Resort, Miami. Florida, 2016).
      11. Livingston, G. et al. Dementia prevention, intervention, and care. Lancet, doi:10.1016/S0140-6736(17)31363-6 (2017).
      12. Crous-Bou, M., Minguillon, C., Gramunt, N. & Molinuevo, J. L. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimer’s research & therapy 9, 71, doi:10.1186/s13195-017-0297-z (2017).
      13. Reiman, E. M. et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. Journal of Alzheimer’s disease : JAD 26 Suppl 3, 321-329, doi:10.3233/JAD-2011-0059 (2011).
      14. Solomon, A. et al. Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. JAMA neurology, doi:10.1001/jamaneurol.2017.4365 (2018).
      15. Lin, P. J., Yang, Z., Fillit, H. M., Cohen, J. T. & Neumann, P. J. Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer’s disease. Health affairs 33, 547-554, doi:10.1377/hlthaff.2013.1276 (2014).

If you have any questions or comments,  we will be pleased to attend you

Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain

+34 983 54 98 96